Crucell completed the purchase of Berna Products (BPC) from Acambis and the consequential termination of the products distribution agreement with BPC for a total consideration of $16.5 million.
BPC was originally established in 1990 by Berna Biotech, the Swiss vaccine company acquired by Crucell in February. It was formed to market Vivotif, Berna’s oral typhoid fever vaccine, in the U.S. and Canada. The company was acquired by Acambis in 2003.
“It makes good sense for Crucell to gain full control of Vivotif’s sales in the U.S., which is the biggest market with the most attractive margins,” points out Crucell’s CEO, Ronald H.P. Brus. “Further, BPC will now assume the role of our sales organization in the U.S. We intend to use the sales and marketing potential the company has already demonstrated so successfully with Vivotif as a platform for future growth in the U.S. , including the potential launch of new products.”